Use of trihydric iron preparations in treatment of anemia in patients with pre-dialysis renal failure
- Authors: Milovanov Y.S1, Milovanova LY.1, Kozlovskaya LV1
-
Affiliations:
- Issue: No 2 (2011)
- Pages: 31-34
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245946
- ID: 245946
Cite item
Full Text
Abstract
Aim. Study of prevalence of anemia and iron deficiency in patients with chronic kidney disease (CKD) stage III - IV and assessment of trihydric iron preparations. Methods. 234 patients with chronic glomerulonephritis (primary and in systemic diseases) were included into the study; all of them had CKD III - IV stage. In 141 patients oral (Maltofer) and intravenous (Venofer) trihydric iron preparations were used.
Results. Anemia was revealed in 185 (84,2%) patients with CKD III - IV stages; prevalence of anemia increased according to glomerular filtration rate (GFR) decrease. In patients with systemic diseases anemia and iron deficiency were found more often even in mild decrease of GFR. Maltofer and Venofer were effective in anemia correction in CKD stage III - IV patients.
Conclusion. Anemia is frequent in CKD stage III - IV patients, especially in systemic diseases; in its correction trihydric iron preparations are effective
Results. Anemia was revealed in 185 (84,2%) patients with CKD III - IV stages; prevalence of anemia increased according to glomerular filtration rate (GFR) decrease. In patients with systemic diseases anemia and iron deficiency were found more often even in mild decrease of GFR. Maltofer and Venofer were effective in anemia correction in CKD stage III - IV patients.
Conclusion. Anemia is frequent in CKD stage III - IV patients, especially in systemic diseases; in its correction trihydric iron preparations are effective
References
- Добронравов В.А., Смирнов А.В. Анемия и хроническая болезнь почек. Анемия. 2005; 2: 2-8
- Ермоленко В.М., Хасабов Н.Н., Михайлова Н.А. Рекомендации по применению препаратов железа у больных с хронической почечной недостаточностью. Анемия. 2005; 2: 9-25
- Шеффер Р.М., Гаше К., Хух Р., Краффт А. Железное письмо: рекомендации по лечению железодефицитной анемии. Анемия. 2005; 2: 37-45
- Шостка Г.Д. Дефицит железа. Анемия. 2004; 1: 11-18
- Fishbane S., Ungureanu V., Maesaka et al. The safety of intravenous iron de[tran in hemodialysis patients. Am. J. Kidney Dis. 1996; 28: 529-534
- Jacobs P., Wood I., Bird A.R. Better tolerance of iron polymaltose complex compared with ferrous sulfate in the treatment of amemia. Hematology. 2000; 5: 77-83
- Langstaff F.J., Geisser P., Heil W.G., Browdler J.M. Treatment of iron-deficiency anemia: a lower incidence of adverse effects with Ferrum Hausmann that ferrous sulphate. Brit. Journal of Clin. Reserch. 1993; 4: 191-198
- NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update. Am. J. Kidney Dis. 2001; 37 (suppl. 1): 182-238
- Revised European Best Practice Guidelines for the Management of anemia in Patients with Chronic Renal Failure. Nephrol. Dial. Transplant. 2004; 19 (suppl. 2): іi2- іi45
- Милованов Ю.С., Козловская Л.В., Милованова Л.Ю. Препараты железа в лечении анемии у больных хронической почечной недостаточность на додиализном этапе. Леч. врач. 2005; 10: 44-48
Supplementary files
